Potent PanKRAS Inhibitor BBO-11818 Preclinical Data Published in Cancer Discovery
summarizeSummary
BridgeBio Oncology Therapeutics announced the publication of detailed preclinical data for its panKRAS inhibitor, BBO-11818, in the peer-reviewed journal Cancer Discovery. The data highlights BBO-11818's potency, selectivity, and its unique ability to target KRAS in both ON and OFF states, demonstrating strong activity against multiple oncogenic KRAS mutants in preclinical models. The company also reiterated encouraging preliminary anti-tumor activities and differentiated safety observed in the ongoing Phase 1 KONQUER-101 trial. This news provides significant scientific validation for a key pipeline asset, building on the general mention of strong preliminary clinical data in the company's recent 10-K filing. The differentiated mechanism of action for BBO-11818 could address critical limitations of existing KRAS inhibitors, representing a material advancement in the treatment of KRAS-driven cancers. Investors should watch for additional Phase 1 data for BBO-11818, expected in the second half of 2026, and the anticipated opening of a combination trial with BBO-10203.
At the time of this announcement, BBOT was trading at $10.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $828.3M. The 52-week trading range was $8.50 to $14.87. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.